Oczyesa (Octreotide)

Oczyesa is a ready-to-use, long-acting subcutaneous depot of octreotide used for the maintenance (long-term) treatment of acromegaly, a condition where a pituitary adenoma (a non-cancerous tumour in a small gland located at the base of the brain) produces too much growth hormone, causing high levels of insulin-like growth factor-1 (IGF-1). This causes excessive growth of tissues and bones and can also cause diabetes, hypertension (high blood pressure), and cardiovascular disease (conditions affecting the heart and blood circulation).

Oczyesa is used in adults who have previously responded to and tolerated treatment with other somatostatin analogues (man-made (synthetic) versions of the hormone somatostatin).

Recommended Dosage:
The standard recommended dosage of Octreotide is 5 mg/kg, administered as a subcutaneous injection over 30 minutes. The treatment schedule starts at Week 0, Week 2, and then continues every 4 weeks thereafter.
In case a dose is missed, it should be administered as quickly as possible. In cases where the missed dose is given within 2 weeks of the scheduled time, patients can resume the original dosing schedule. However, if it is administered after 2 weeks, the therapy should be continued at every 4-week intervals from the new date.
Physicians are advised to re-evaluate the patient’s therapy at least yearly to confirm whether ongoing treatment provides continued clinical benefit. Oczyesa may be used alone or in combination with hydroxyurea, depending on the patient’s medical needs and the physician’s recommendation.

• Treatment with Octreotide may sometimes cause sudden infusion-related reactions such as nausea, fever, dizziness, chills, or difficulty in breathing. If these signs occur, the infusion must be stopped quickly, and medical attention must be provided to manage the reaction safely.
• This therapeutic drug can interfere with certain laboratory diagnostic tests and potentially alter the results of these tests. Patients should always inform their clinician and laboratory staff about ongoing treatment before undergoing any medical tests to ensure accurate interpretation and avoid misdiagnosis.
• Octreotide should only be used during pregnancy or breastfeeding if the expected benefits clearly outweigh potential risks to the mother and baby. It is not yet known whether the drug passes into breast milk, so medical advice is essential before use.
• The safety and effectiveness of this therapeutic drug in children have not yet been completely established. Pediatric use should be considered only with extreme caution, under expert supervision, and when no better alternatives exist. Close monitoring is needed during the entire treatment period.
• There is limited clinical data on the use of Octreotide in patients aged 65 years and older. Since elderly patients may have more comorbidities or be on multiple medications, they may face higher risks of drug interactions and should be monitored closely.

What documents are required to import OCZYESA to India?

OCZYESA (octreotide hydrochloride) injection can be imported by patients or government hospitals in the name of the patients only.
The following documentation is required to import the product:

• A valid prescription from a qualified doctor.
• Patients diagnostic reports
• Patient ID proof (issued by the government of India)

How does the order get confirmed?

The order will be confirmed only after the receipt of:

• A valid prescription from the Doctor
• Import permit if applicable

Is OCZYESA available in India?

OCZYESA (octreotide hydrochloride injections) is a (prescription drug, prescription medication, or prescription medicine) pharmaceutical drug that legally requires a medical prescription to be dispensed.

IPN (Indian Pharma Network) helps import cancer medicines on the named patient supply (NPS). Indian Pharma Network is the facilitator, providing input

• On availability of Oczyesa in India (Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Pune, etc.)
• On availability in Gulf countries (Bahrain, Oman, Qatar, Kuwait, Iraq, Saudi Arabia, and the UAE).
• Medicine Price.
• Finding Genuine and reliable sources from the USA, Canada, Europe, and Australia
• Ensuring 100% transparency.

OCZYESA can be made available to patients, doctors, and hospitals in Mumbai, Goa, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, and Pune, and other cities in India. The order will be confirmed only after the receipt of a valid prescription from the doctor and an import permit.

IPN (Indian Pharma Network) can facilitate the supply of OCZYESA (prescription medicines) to all locations in the world and India after fulfilling the legal requirements (if applicable).

Please contact +91-9310090915 | Toll-Free Number: 1800-889-1064 or write us at info@indianpharmanetwork-in-253190.hostingersite.com for Oczyesa 20 mg injection price in India.

We guarantee quality and delivery anywhere in the world as per the buyer’s requirements.

Indian Pharma Network can source OCZYESA (Cancer Treatment Medicines) from across the globe and can supply. Indian Pharma offers its customers worldwide access to the best available treatment.

Indian Pharma Network (IPN) can dispense any valid prescription in the shortest possible time. All prescriptions are dispensed and checked by registered pharmacists and dispatched to the Patient’s address only from New Delhi, India.

What is the Generic Name for the trade name drug Oczyesa®?

Octreotide hydrochloride is the Generic Name for the trade name drug Oczyesa®.

What is the Manufacturer’s Name of Oczyesa®?

Oczyesa® is manufactured by Camurus.

Is Oczyesa approved by the FDA?

No — Oczyesa (octreotide subcutaneous depot, CAM2029) has not yet received FDA approval in the United States, but it has been approved in the European Union.

When did the European Commission grant full marketing

authorization for Oczyesa in the European Union?
Yes — Oczyesa has been approved by the European Commission for use within the European Union. Specifically, the European Commission granted full marketing authorization for Oczyesa on 30 June 2025, following a positive opinion from the EMA’s CHMP in April 2025

What is the dosage and form of Oczyesa® supplied?

Oczyesa is supplied for Injection: 20 mg (10 mg/mL) solution in a pre-filled syringe (glass) in a pre-filled pen for subcutaneous (SC) use.

What are the most common side effects of Oczyesa® 20 mg injection?

The most commonly reported side effects of Oczyesa® are flatulence (gas), abdominal (belly) pain, constipation, headache, nausea, diarrhoea, cholelithiasis, and reactions at the injection site.

How much does Oczyesa® 20 mg injection cost in India?

Oczyesa® is not yet approved in India. However, patients in India can legally access it through the provision called the Named Patient Program (NPP). Oczyesa prices may fluctuate over time because of market dynamics and regulatory changes. For the most transparent and latest Oczyesa 20 mg cost in India, please call/WhatsApp +91-9310090915 or send an email to info@indianpharmanetwork-in-253190.hostingersite.com.

Can Oczyesa® 20 mg injections be available in SAARC countries?

Apart from Gulf countries, Oczyesa® can be accessed through import provisions like the Named Patient Program (NPP) in SAARC countries (India, Afghanistan, Maldives, Nepal, Bangladesh, Bhutan, Pakistan, and Sri Lanka). Indian Pharma Network (IPN) can help facilitate the legal supply of Oczyesa® injection in these countries. We help provide legal access to this therapeutic drug through our reliable channels.

Is it safe to buy Oczyesa® 20 mg injection online in India?
Yes, one can buy Oczyesa 20 mg online in India at the lowest price from the Indian Pharma Network (IPN) if this medicinal product is not yet registered or available in their country. We can help facilitate the legal supply of Oczyesa® injection through legal channels.

What are the storage conditions of Oczyesa® 20 mg injections?
Store the pre-filled pens at room temperature, typically between 20 °C to 25 °C (68 °F to 77 °F). It is important to protect this therapeutic drug from light to maintain stability.